Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Johnson and Johnson
Deloitte
Citi
Mallinckrodt

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,660,726

« Back to Dashboard

Which drugs does patent 6,660,726 protect, and when does it expire?

Patent 6,660,726 protects ENJUVIA and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 6,660,726
Title: Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
Abstract:Novel estrogenic compounds of Formula I are provided. ##STR1## wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 is lower alkyl; R.sub.3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R.sub.4 through R.sub.13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R.sub.14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R.sub.1 is hydroxy, the hydroxy or ester substituent may have either an .alpha. or a .beta. orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Inventor(s): Hill; Edward N. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/800,614
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,660,726
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,660,726

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,660,726

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 377605 ➤ Sign Up
Australia 4733701 ➤ Sign Up
Canada 2402667 ➤ Sign Up
Germany 60131253 ➤ Sign Up
European Patent Office 1263770 ➤ Sign Up
World Intellectual Property Organization (WIPO) 0168669 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKesson
Fuji
US Department of Justice
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.